| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.007 | 0.9 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | ETP-46464 | CTRPv2 | pan-cancer | AAC | -0.0073 | 0.9 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | Ko-143 | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | 0.0097 | 0.9 |